1. Home
  2. EPD vs REGN Comparison

EPD vs REGN Comparison

Compare EPD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enterprise Products Partners L.P.

EPD

Enterprise Products Partners L.P.

N/A

Current Price

$38.36

Market Cap

82.4B

Sector

Utilities

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$958.53

Market Cap

84.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPD
REGN
Founded
1968
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.4B
84.3B
IPO Year
1998
1995

Fundamental Metrics

Financial Performance
Metric
EPD
REGN
Price
$38.36
$958.53
Analyst Decision
Buy
Buy
Analyst Count
23
28
Target Price
$41.67
★ $977.93
AVG Volume (30 Days)
★ 3.8M
900.8K
Earning Date
10-29-2026
10-30-2026
Dividend Yield
★ 5.99%
0.40%
EPS Growth
★ 106.96
8.19
EPS
2.38
★ 37.37
Revenue
★ $52,596,000,000.00
$5,872,227,000.00
Revenue This Year
$25.95
$30.96
Revenue Next Year
$5.14
$7.28
P/E Ratio
★ $15.74
$25.47
Revenue Growth
N/A
★ 20.82
52 Week Low
$31.35
$591.52
52 Week High
$40.17
$991.73

Technical Indicators

Market Signals
Indicator
EPD
REGN
Relative Strength Index (RSI) 59.77 68.96
Support Level $36.06 $747.82
Resistance Level $38.84 $991.73
Average True Range (ATR) 0.77 36.85
MACD 0.08 5.63
Stochastic Oscillator 66.71 82.95

Price Performance

Historical Comparison
EPD
REGN

About EPD Enterprise Products Partners L.P.

Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: